Controlling Malodour In Fungating Wounds Using A Cinnamon-Based Dressing: Observational Study

December 6, 2022 updated by: CEMAG Care

The purpose of the study is to observe the contribution of the cinnamon dressing to the reduction of the discomfort associated with the odour felt by the patient and carers.

This prospective study aims to collect data on patients living with a malodorous fungating wound. Quality of life tools will be used to assess the impact of the cinnamon dressing on managing malodorous fungating wounds.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

There are several anti-odour treatments on the market for managing malodorous wounds but no conclusive data on their efficacy is available. Current treatments like charcoal dressing or topical antimicrobials do not completely manage bad odours in particular for tumoral wounds. In the case of malodorous wounds, the ideal management plan would therefore be to reduce (or neutralise) bad odours, and modify any residual odour so that it becomes more pleasant than unpleasant.

Cinesteam® was specially developed to reduce and manage malodorous wounds. Cinesteam® is a secondary dressing that eliminates unpleasant odours and masks any residual odours with the spice's natural fragrance. This dressing also absorbs excess exudates released by the wound.

The aim of this post-market observational study is to observe the performance of Cinesteam® in controlling malodour in fungating wounds. Patients with malodourous, fungating wounds, above 18 years with a discomfort score of >40/100, with cognitive ability to participate and consent, will be eligible to participate in the study. The study will be conducted on eligible patients in the North East of England, treated at the Newcastle upon Tyne Hospitals NHS Foundation Trust, either as inpatients or in its surrounding community.

The duration of patient participation in the study is 14 days. The research nurse will visit patients on Day0 and perform wound assessment, apply Cinesteam dressing over the standard care primary dressing and answer questionnaires on odour, and discomfort, and also help patients with questionnaires on odour, discomfort, appetite and Quality of life.

The research nurse will change Cinesteam dressing on Day 1, Day 7 +/- 48 hours, and Day 14 +/- 48 hours and perform follow-up assessments on patients' wound condition. Patients or their caregivers who usually change the patient's dressing will change the primary dressing and Cinesteam dressing in-between the research nurse's assessment visits. They will keep a record of these dressing changes in the diary provided.

Study Type

Interventional

Enrollment (Anticipated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Newcastle Upon Tyne, United Kingdom, NE7 7DN
        • The Newcastle Upon Tyne Hospital NHS Foundation Trust
        • Principal Investigator:
          • Fania Pagnamenta, Dr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient > 18 years old with malodorous fungating wounds
  • Discomfort > 40/100 expressed by the patient);
  • Patients who have capacity to consent;
  • Patients who are cognitively able and willing to participate;
  • Patients who have a good command of the English language.

Exclusion Criteria:

  • Patient with pressure ulcers, leg ulcers, diabetic feet ulcers;
  • Terminally ill patients whose life expectancy is less than the duration of the protocol;
  • Patients having had metronidazole treatment for fewer than 3 days before enrolment in the study;
  • Patients who are unable or willing to participate;
  • Anosmic patient (with no sense of smell);
  • Patient with cinnamon allergy;
  • Persons deprived of their liberty or under guardianship;
  • Unable to take part in study procedures for whatever reason;
  • Pregnant or lactating women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cinnamon
Cinnamon-based Secondary dressing

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change from baseline patient wound odour at different timepoints using a Visual Analogue Scale (VAS-100mm scale), from 0 (no smell) to 100 (worst smell imaginable)
Time Frame: Baseline visit, one day, 7 and 14 days after baseline visit
Baseline visit, one day, 7 and 14 days after baseline visit

Secondary Outcome Measures

Outcome Measure
Time Frame
Change from baseline patient discomfort associated with the wound odour at different timepoints using a Visual Analogue Scale (VAS-100mm scale), from 0 (no discomfort) to 100 (Unbearable discomfort during the sleeping and waking hours)
Time Frame: Baseline visit, one day, 7 and 14 days after baseline visit
Baseline visit, one day, 7 and 14 days after baseline visit
Change from baseline patient quality of life at different timepoints using the questionnaire of EuroQol 5 Dimension 5 Level (EQ-5D-5L)
Time Frame: Baseline visit, one day and 14 days after baseline visit
Baseline visit, one day and 14 days after baseline visit
Change from baseline investigator-rating the strength of the wound odour and smell at different timepoints using TELERTM from none odour to very strong odour.
Time Frame: Baseline visit, one day, 7 and 14 days after baseline visit
Baseline visit, one day, 7 and 14 days after baseline visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

February 1, 2023

Primary Completion (Anticipated)

September 1, 2023

Study Completion (Anticipated)

October 1, 2023

Study Registration Dates

First Submitted

November 28, 2022

First Submitted That Met QC Criteria

December 6, 2022

First Posted (Estimate)

December 14, 2022

Study Record Updates

Last Update Posted (Estimate)

December 14, 2022

Last Update Submitted That Met QC Criteria

December 6, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CIN-S22001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Wound

Subscribe